JWH-307

JWH-307 is a synthetic cannabinoid from the naphthoylindole family, which acts as a full agonist at both the CB₁ and CB₂ cannabinoid receptors, but with some selectivity for CB₂. It was discovered by and named after John W. Huffman.

Chemistry[edit | edit source]

JWH-307 belongs to the naphthoylindole family of synthetic cannabinoids. It is structurally related to compounds such as JWH-018 and JWH-073, which are also naphthoylindoles.

Pharmacology[edit | edit source]

JWH-307 acts as a full agonist at the CB₁ and CB₂ cannabinoid receptors. It has some selectivity for CB₂, with a binding affinity of 8.9nM at CB₁ and 5.2nM at CB₂.

Effects[edit | edit source]

The effects of JWH-307 in humans are not well studied. However, due to its full agonist activity at the cannabinoid receptors, it is likely to produce effects similar to those of tetrahydrocannabinol (THC), the main psychoactive compound in cannabis.

Legal status[edit | edit source]

JWH-307 is a controlled substance in several countries, including the United States, where it is classified as a Schedule I drug under the Controlled Substances Act.

See also[edit | edit source]

JWH-307 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.